Kimberly Westrich

National Health Council — United States

Economics, Econometrics and Finance · Social Sciences

12h-index576citations66works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(45), Healthcare Policy and Management(13), Pharmaceutical Economics and Policy(13), Healthcare cost, quality, practices(13), Economic and Financial Impacts of Cancer(12)

Publications66 total

Patient engagement in managed care pharmacy: Putting policy into practice
Journal of Managed Care & Specialty Pharmacy·2025Open Access
The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022
INQUIRY The Journal of Health Care Organization Provision and Financing·2025Open Access
HPR45 The Cost of 340B to States
Value in Health·2025
HPR13 Are Commercial Insurance Premiums Associated With the 340B Drug Pricing Program?
Value in Health·2025
The time is now: Addressing health inequities in the workforce
Journal of Managed Care & Specialty Pharmacy·2025· 1 cited
The time is now: Addressing health inequities in the workforce
Journal of Managed Care & Specialty Pharmacy·2025Open Access
Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: contextualizing drug spending changes
Journal of Medical Economics·2024Open Access
Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States
Journal of Comparative Effectiveness Research·2024· 3 citedOpen Access
HTA14 Payer Perspectives on the Use of ICER Evidence Reports Over the Past 24 Months
Value in Health·2024Open Access
HPR11 Revenue-Sharing or Revenue Lost? The Hidden Costs of 340B to Employers
Value in Health·2024Open Access
P61 Payer Willingness to Pay for Novel Value Attributes: The Impact of Higher WTP Thresholds on ICER’s Cost-Effectiveness Determinations
Value in Health·2024Open Access
MSR56 Navigating Uncertainty: Trends in ICER’s Evidence Ratings
Value in Health·2024Open Access
HTA74 Better Late Than Never? Payer Appetite and Vision for a National Value Assessment Body
Value in Health·2024
HTA16 A Preliminary Assessment of ICER's New HTA Methods That Support Health Equity
Value in Health·2024Open Access
Association between adherence with oral anticancer medications and short-term health care resource utilization: A 2010-2018 claims-based analysis
Journal of Managed Care & Specialty Pharmacy·2024· 3 citedOpen Access
HTA20 Deconstructing ICER Value Assessments: Which Components Do Payers Value Most?
Value in Health·2023
HTA15 Beyond Value Assessment: Payer Perceptions of ICER’s Policy Initiatives
Value in Health·2023· 1 citedOpen Access
HTA51 Impact of ICER Assessments on Payer Decision Making in the United States
Value in Health·2023Open Access
EE317 Examining ICER's Inclusion of Novel Value Factors: Do They Move the Needle on Value Appraisals?
Value in Health·2023Open Access
HTA18 An Assessment of the Evolving Methods and Role of Health Equity Factors in ICER’s Final Evidence Reports
Value in Health·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Robert W. Dubois(25), Lisabeth Buelt(8), Adam Lustig(6), Jerry Penso(5), Mark McClellan(4), Patrick Campbell(4), Peter J. Neumann(3), Anita Chawla(3), Tom Valuck(3), Ami Vyas(3), Stephen Kogut(3), Megha A. Parikh(3), Amanda Green(3), Marv Feldman(3), Bruce W. Sherman(3), Brian Sils(3), V Loo(3), Adrian Towse(2), Andrew Descoteaux(2), Chrisanne Wilks(2)